A biobank of patient-derived pediatric brain tumor models

Area of Science:

• Pediatric Oncology
• Cancer Genomics
• Translational Research

Background:

• Pediatric brain tumors are a major cause of cancer mortality in children.
• Genomic insights have identified molecular subgroups and drivers, suggesting new therapeutic avenues.
• Effective evaluation of novel treatments requires preclinical models that capture tumor heterogeneity.

Purpose of the Study:

• To generate and characterize patient-derived orthotopic xenograft (PDOX) models and cell lines for pediatric brain tumors.
• To assess the fidelity of these models in representing the original human tumors.
• To establish a resource for studying pediatric brain tumor biology and testing therapeutics.

Main Methods:

• Generation of 30 PDOX models and seven cell lines from pediatric brain tumors through the Children's Oncology Group ACNS02B3 study.
• Comprehensive characterization including histology, immunohistochemistry, gene expression, DNA methylation, copy number analysis, and mutational profiling.
• Evaluation of in vivo drug sensitivity in relation to molecular subgroups and genetic alterations.

Main Results:

• The generated PDOX models and cell lines represent 14 distinct molecular subgroups of pediatric brain tumors.
• Models demonstrated high fidelity to patient tumors across multiple molecular and histological levels.
• In vivo drug sensitivity correlated with specific molecular subgroups and genetic alterations, validating targeted therapeutic potential.

Conclusions:

• The developed preclinical models are highly representative of pediatric brain tumor heterogeneity.
• These models offer a valuable resource for investigating oncogenic drivers in pediatric brain tumors.
• The findings support the use of these models for evaluating novel therapeutic strategies against childhood brain cancers.